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Objectives: To improve quality in breast cancer care, large numbers of quality indicators are collected per hospital, but
benchmarking remains complex. We aimed to assess the validity of indicators, develop a textbook outcome summary
measure, and compare case-mix adjusted hospital performance.
Methods: From a nationwide population-based registry, all 79 690 nonmetastatic breast cancer patients surgically treated
between 2011 and 2016 in 91 hospitals in The Netherlands were included. Twenty-one indicators were calculated and
their construct validity tested by Spearman’s rho. Between-hospital variation was expressed by interquartile range (IQR),
and all valid indicators were included in the summary measure. Standardized scores (observed/expected based on case
mix) were calculated as above (.100) or below (,100) expected. The textbook outcome was presented as a continuous
and all-or-none score.
Results: The size of between-hospital variation varied between indicators. Sixteen (76%) of 21 quality indicators showed
construct validity, and 13 were included in the summary measure after excluding redundant indicators that showed
collinearity with others owing to strong construct validity. The median all-or-none textbook outcome score was 49% (IQR
42%-54%) before and 49% (IQR 48%-51%) after case-mix adjustment. From the total of 91 hospitals, 3 hospitals were
positive (3%) and 9 (10%) were negative outliers.
Conclusions: The textbook outcome summary measure showed discriminative ability when hospital performance was
presented as an all-or-none score. Although indicator scores and outlier hospitals should always be interpreted cautiously, the
summary measure presented here has the potential to improve Dutch breast cancer quality indicator efforts and could be
implemented to further test its validity, feasibility, and usefulness.
Keywords: breast cancer, quality of care, quality indicators, hospital variation.
VALUE HEALTH. 2020; -(-):-–-Introduction
There is a growing demand for publishing information on
quality of care to drive quality improvement.1 Monitoring and
publishing quality indicator information has previously led to
quality improvement.2–4 Further quality improvement is expected
from comparing and ranking hospitals.5,6. Nevertheless, hospitals
can score high on one indicator but low on another indicator,
resulting in a complex web of information and challenges for
benchmarking. The case mix may also influence variation seen in
indicator scores between hospitals.7–10 Interpretation and usabil-
ity of hospital performance data are therefore difficult, and the
impact on healthcare providers and consumers is limited.11–15
Studies revealed that patients prefer a summary measure to gain
insight into the performance of a hospital.16–18 The same can be
expected from other parties making use of performance data asss correspondence to: Linetta B. Koppert, Department of Surgery, Erasmus M
rt@erasmusmc.nl
15/$36.00 - see front matter Copyright ª 2020, ISPOR–The Professional So
doi.org/10.1016/j.jval.2020.05.011healthcare providers, health insurance companies, and govern-
mental agencies. We believe that a summary measure describing
quality with one value has the potential to increase the under-
standing and impact of hospital performance data.
One important prerequisite for quality indicators is their
validity. Validity means that indicators measure what they
claim to measure.19 One type of validity is construct validity,
which evaluates the relation between indicators that measure
the same underlying concept.20 Indicators lacking construct
validity or indicators that are redundant may be excluded from
the summary measure. A commonly used approach to
construct a summary measure is the textbook outcome, rep-
resenting patients in whom optimal (ie, textbook) health out-
comes are realized.21 The textbook outcome can be presented
as a continuous score (ie, the average number of indicators
with a positive result) or an all-or-none score (ie, the numberC Cancer Institute, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Email:
ciety for Health Economics and Outcomes Research. Published by Elsevier Inc.
2 VALUE IN HEALTH - 2020of patients with a positive result for all indicators) per
hospital.22
Breast cancer care quality improvements efforts in The
Netherlands are led by the National Breast cancer working group
Netherlands (NABON) Breast Cancer Audit (NBCA). Since 2011, a
set of structure, process, and outcome indicators are defined and
regularly updated by multidisciplinary group consensus.23 The
NBCA provides regular feedback on the quality indicator scores to
the individual hospitals. We aimed to develop a textbook outcome
type of summary measure by construct validity testing of the
NBCA set of breast cancer process and outcome quality indicators.
Then, hospital performance was assessed by comparing and
ranking them based on their case mix–adjusted textbook outcome
standardized score and presented by both the continuous and
all-or-none approach.Methods
Data
From the NBCA, patient-level data were retrieved of all
patients with primary invasive breast cancer or ductal carcinoma
in situ (DCIS) who were surgically treated and diagnosed in all 91
hospitals between January 2011 and August 2016 in The
Netherlands. In this period, 9 hospitals fused, resulting in a
different total number of hospitals in each year. Hospitals choose
to register the data themselves directly into a web-based system
(20%-30% of all hospitals) provided by Dutch Institute for Clinical
Auditing or have it registered by the Netherlands Comprehensive
Cancer Organisation as part of the Netherlands Cancer Registry
(NCR). All new malignancies have been registered in the NCR on a
national level since 1989. All hospitals can review the data for
inconsistencies. A third party anonymized all data before it was
made available for this study. The data included the following: sex,
age, World Health Organization performance status, method of
tumor detection, palpability, type of surgery/surgeries, multi-
focality, histology, tumor size in millimeter, Bloom and Richardson
differentiation grade, hormone and Her2neu receptor status,
clinical and pathological tumor node metastasis staging,24 radia-
tion treatment, chemotherapy, and hormonal therapy.
Quality Indicators
The NBCA quality indicator set evolved over the years. Even
though all indicators used between 2011 and 2017 were consid-
ered, only those generally believed to represent quality of care
were studied.23 For example, the indicator percentage of patients
with magnetic resonance imaging (MRI) was not suitable, because
a higher or lower score is not associated with better quality of
care. For each patient, an indicator could be scored as positive or
negative. For each hospital, indicator scores were calculated by
dividing the numerator (ie, the number of patients with a positive
score) by the denominator (ie, the number of eligible patients) as
defined by the publicly available NBCA manual (Table 1).25 Pa-
tients with distant metastasis at time of diagnosis were excluded
from all denominators. Indicator scores presented here may
deviate from the NBCA reports.
Statistical Analysis
Whether the patient, tumor, and treatment characteristics
differed between hospitals was tested by Kruskal-Wallis test.
Hospital variation referred to between-hospital variation, and
within-hospital variation was not studied. Indicator scores and
hospital variation were presented by median, interquartile range
(IQR), and range. The effect of number of events on hospitalvariationwas evaluated by presenting results from the total cohort
(2011-2016) and from 1 year of data only (2015, since 2016
included data until August).
Construct Validity
Members of NABON were consulted for their expert opinions
regarding indicators that may measure the same underlying
construct. The direction of association (ie, negative or positive)
was defined a priori. Construct validity was tested by Spearman
correlation coefficient, and 95% confidence interval (CI) was
obtained by bootstrapping (1000 random replicas). Construct
validity was considered present if statistically significant in the
expected direction of association. A Spearman’s rho ,0.40 was
defined as a weak correlation, 0.40 to 0.59 was described as
moderate, and .60 was strong.26
Textbook Outcome
Construct valid indicators were included in the summary
measure textbook outcome. If a patient scored positive on all in-
dicators, a textbook outcome was achieved. For most indicators,
the denominator is different and therefore a patient did score
positive if this patient was not included in the denominator of the
indicator of interest. For example, patients with DCIS only were
not included in the denominator of irradical breast-conserving
surgery (BCS) in invasive disease, but did score positive. This
enabled building a single textbook outcome summary measure,
otherwise hospitals could not be allocated 1 summary score for all
their different types of breast cancer patients with different
treatments. Textbook outcome was presented as a continuous
score (ie, the median number of indicators with a positive score)
and as an all-or-none score (ie, the percentage of patients scoring
positive on all indicators thus achieving textbook outcome).
Case Mix
Case-mix adjustment was performed by multivariable linear
regression analysis for the continuous textbook outcome and by
logistic regression analysis for the all-or-none textbook outcome.
All general patient and tumor characteristics were used as case-
mix factors: age, histology, pathological tumor and node stage,
differentiation grade, multifocality, and estrogen and Her2neu
receptor status. For each hospital, the standardized rate and 95% CI
for textbook outcome was calculated by dividing the observed
score by the expected score. The expected score was the mean
from all hospitals for the unadjusted model and the predicted
probability for an individual hospital for the case-mix adjusted
model. A standardized rate larger than 100 means more textbook
outcomes (ie, better-achieving hospital) and a standardized rate
smaller than 100 means less textbook outcomes (ie, poorer-
achieving hospital) compared to the average or expected. The
standard error of the standardized rate was calculated by dividing
the standardized rate by the root of the number of events.
Statistical analysis was performed by IBM SPSS Statistics
version 22.0 (IBM, Armonk, New York) and R version 3.0.1 (R
Foundation of Statistical Computing, Vienna, Austria). All P values
were 2-sided, and P values of ,.05 were considered statistically
significant. For this type of study, approval from a medical ethical
committee was not required.
Results
A total of 79 690 patients had invasive breast cancer or DCIS
and were surgically treated in 91 different hospitals between
January 2011 and August 2016 in The Netherlands (see Appendix
Table A in Supplemental Materials found at https://doi.org/10.1
Table 1. Definition of NBCA Quality Indicators 2011-2017.
QI Short name Definition
Radiology
1 BI-RADS classification Numerator: number of patients with
BI-RADS category reported in diagnostic
phase on mammography, ultrasound, or
breast MRI. Denominator: number of
patients surgically treated for invasive
breast cancer or DCIS.
2 MRI in neoadjuvant chemotherapy Numerator: number of patients with
breast MRI prior to start of neoadjuvant
chemotherapy. Denominator: number of
patients with invasive breast cancer
treated with neoadjuvant chemotherapy.
Pathology
3 Full pathology report as defined Numerator: number of patients with
standard pathology report including
information about ER%, PR%, HER2,
grade, tumor size, resection margin, and
number of positive lymph nodes.
Denominator: number of patients with a
pathology report of invasive breast
cancer of at least 1 cm without
neoadjuvant therapy.
Surgery/plastic surgery
4 Irradical BCS in invasive disease Numerator: number of patients with
more than focally positive margins* after
first BCS. Denominator: number of
patients treated with BCS for invasive
non-metastasized breast cancer and
without neoadjuvant chemotherapy.
5 Irradical BCS in DCIS Numerator: number of patients with
positive margins after first BCS.
Denominator: number of patients treated
with BCS for DCIS.
6 Reexcision after BCS for invasive disease Numerator: number of patients with
reexcision. Denominator: number of
patients with BCS for invasive non-
metastasized breast cancer without
neoadjuvant chemotherapy.
7 Reexcision after BCS for DCIS Numerator: number of patients with
reexcision. Denominator: number of
patients with BCS for DCIS.
8 Breast contour–preserving treatment Numerator: number of patients with (1)
breast-conserving surgery including
re-lumpectomies without neoadjuvant
chemotherapy, (2) neoadjuvant
chemotherapy, and (3) mastectomy with
direct breast reconstruction.
Denominator: number of patients with
invasive non-metastasized breast cancer
with and without neoadjuvant
chemotherapy.
9 Immediate breast reconstruction in DCIS Numerator: number of patients with
immediate breast reconstruction.
Denominator: number of patients with a
primary mastectomy for DCIS.
10 Immediate breast reconstruction in
invasive disease
Numerator: number of patients with
immediate breast reconstruction.
Denominator: number of patients with a
primary mastectomy for invasive breast
cancer.
continued on next page
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Table 1. Continued
QI Short name Definition
Radiotherapy
11 Seen by radiation oncologist prior to
neoadjuvant chemotherapy
Numerator: number of patients seen by
radiation oncologist prior to neoadjuvant
chemotherapy. Denominator: number of
patients with invasive breast cancer
treated with neoadjuvant chemotherapy,
surgery, and postoperative radiotherapy.
12 Radiotherapy for locally advanced Numerator: number of patients treated
with radiotherapy. Denominator: number
of patients with invasive non-
metastasized locally advanced† breast
cancer and treated with mastectomy.
General
13 Preoperative MDT meeting Numerator: number of patients for whom
the information in the registry is complete
and discussed in a preoperative MDT
meeting. Denominator: number of
surgically treated patients with primary
invasive breast cancer or DCIS.
14 Postoperative MDT meeting Numerator: number of patients for whom
the information in the registry is complete
and discussed in a postoperative MDT
meeting. Denominator: number of
surgically treated patients with primary
invasive breast cancer or DCIS.
15 Neoadjuvant chemotherapy within 5
weeks of diagnosis
Numerator: number of patients receiving
neoadjuvant chemotherapy within #5
weeks after diagnosis. Denominator:
number of patients with neoadjuvant
chemotherapy for invasive non-
metastasized breast cancer.
16 Surgery within 5 weeks (without
reconstruction) of diagnosis
Numerator: number of patients receiving
surgery within 5 weeks of diagnosis.
Denominator: number of patients with
primary surgery without immediate
breast reconstruction for invasive non-
metastasized breast cancer or DCIS and
without neoadjuvant chemotherapy.
17 Surgery with breast reconstruction within
5 weeks of diagnosis
Numerator: number of patients receiving
surgery within 5 weeks of diagnosis.
Denominator: number of patients with
primary surgery with breast
reconstruction‡ for invasive non-
metastasized breast cancer or DCIS and
without neoadjuvant chemotherapy.
18 Radiotherapy within 5 weeks of final
operation
Numerator: number of patients receiving
radiotherapy within #5 weeks after
surgery. Denominator: number of
patients with invasive non-metastasized
breast cancer or DCIS treated with
surgery and radiotherapy (without
chemotherapy between the 2
treatments).
19 Radiotherapy within 5 weeks of last
chemotherapy
Numerator: number of patients receiving
radiotherapy within #5 weeks after
chemotherapy. Denominator: number of
patients with invasive non-metastasized
breast cancer with chemotherapy and
radiotherapy.
continued on next page
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Table 1. Continued
QI Short name Definition
20 Chemotherapy within 5 weeks of final
operation
Numerator: number of patients receiving
chemotherapy within #5 weeks after
surgery. Denominator: number of
patients with invasive non-metastasized
breast cancer with surgery and
chemotherapy (without radiotherapy
between the 2 treatments).
21 Chemotherapy within 5 weeks of last
radiotherapy
Numerator: number of patients receiving
chemotherapy within #5 weeks after
radiotherapy. Denominator: number of
patients with invasive non-metastasized
breast cancer with radiotherapy and
chemotherapy.
BCS indicates breast-conserving surgery; BI-RADS, Breast Imaging-Reporting and Data System; DCIS, ductal carcinoma in situ; MDT, multidisciplinary team; MRI,
magnetic resonance imaging; QI, quality indicator.
*More than focally positive margins is defined as tumor touching the inked margin over a length of 4 mm or more.
†Clinical T3, T4, any N, M0 and T, N2-3, M0 with $cT3, or $pT2 (except for pT3N0).
‡Including both primary and secondary mastectomies and both prosthesis and autologous breast reconstruction.
-- 5016/j.jval.2020.05.011). The subcohort of 2015 consisted of 15 101
patients who were treated in 82 different hospitals. Variation
between hospitals was present for all 21 quality indicators (Fig. 1;
Appendix Table B in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2020.05.011). Nevertheless, the magnitude of
the variation was influenced by the number of patients in the
following indicators: the IQR of between-hospital variation for
irradical BCS in invasive disease was 2.1 to 4.2 in the total cohort
and 0.8 to 4.6 in the subcohort; for irradical BCS in DCIS it was 16
to 24 and 11 to 29, respectively, for reexcision after BCS for inva-
sive disease 5.0 to 8.9 and 4.2 to 9.0, for reexcision after BCS for
DCIS 11 to 19 and 5 to 22, and for chemotherapy within 5 weeks of
final operation 54 to 83 and 50 to 100, respectively.
Construct Validity
A total of 14 correlations were hypothesized to measure the
same underlying construct in the set of 21 indicators, and some
indicators were used in more than 1 correlation. Nine correlations
were found to be significant in the subcohort of 2015 and 11
correlations in the total cohort of 2011 to 2016 representing 16
(76%) of the indicators (Fig. 2; Appendix Table C in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.05.011). A
strong correlation was found between irradical BCS in invasive
disease and reexcision after BCS for invasive disease (Spearman’s
rho 0.60, P ,.001), breast contour–preserving treatment and
immediate breast reconstruction in invasive disease (Spearman’s
rho 0.62, P,.001), and immediate breast reconstruction in invasive
disease and immediate breast reconstruction in DCIS (Spearman’s
rho 0.77, P ,.001). A moderate correlation was found between
preoperative multidisciplinary team (MDT) meeting and post-
operative MDT meeting (Spearman’s rho 0.48, P,.001), irradical
BCS in invasive disease and irradical BCS in DCIS (Spearman’s rho
0.44, P,.001), irradical BCS in DCIS and reexcision after BCS in
DCIS (Spearman’s rho 0.52, P,.001), and surgery (without recon-
struction) within 5 weeks of diagnosis and surgery with breast
reconstruction within 5 weeks of diagnosis (Spearman’s rho 0.51,
P,.001). A weak correlation was found between the full pathology
report and Breast Imaging-Reporting and Data System classifica-
tion (Spearman’s rho 0.31, P=.002), being seen by a radiation
oncologist prior to neoadjuvant chemotherapy, and MRI in neo-
adjuvant chemotherapy (Spearman’s rho 0.28, P=.007), reexcision
after BCS in invasive disease and reexcision after BCS in DCIS(Spearman’s rho 0.37, P,.001), neoadjuvant chemotherapy within
5 weeks of diagnosis and surgery within 5 weeks (without
reconstruction) of diagnosis (Spearman’s rho 0.22, P=.040). No
correlation was found between irradicality in invasive disease and
breast contour–preserving treatment, radiotherapy within 5
weeks of final operation and radiotherapy within 5 weeks of last
chemotherapy, and chemotherapy within 5 weeks of final opera-
tion and chemotherapy within 5 weeks of last radiotherapy.
Textbook Outcome
All indicators showing weak or moderate construct validity
were included in the summary measure. From the indicators with
strong construct validity, 1 of the 2 was included. Indicators
lacking construct validity were excluded. The following 13 in-
dicators were included in the summary measure textbook
outcome: Breast Imaging-Reporting and Data System classifica-
tion, MRI in neoadjuvant chemotherapy, full pathology report,
irradical BCS in invasive disease, irradical BCS in DCIS, breast
contour–preserving treatment, seen by radiation oncologist prior
to neoadjuvant chemotherapy, radiotherapy for locally advanced,
preoperative MDT meeting, postoperative MDT meeting, neo-
adjuvant chemotherapy within 5 weeks of diagnosis, surgery
(without reconstruction) within 5 weeks of diagnosis, and surgery
with breast reconstruction within 5 weeks of diagnosis (see Ap-
pendix Table D in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2020.05.011). Textbook outcome was achieved
in 38 956 (48.9%) patients; 29 142 (36.6%) patients scored positive
on 12 indicators, 9313 (11.7%) on 11, 1979 (2.5%) on 10 276 (0.3%)
on 9, 21 patients on 8 indicators, and 3 patients scored positive on
7 indicators. Hospital volume was not correlated with achieving
textbook outcome (Pearson correlation of 0.05 and P=.404). The
median (IQR) of the continuous textbook outcome score was 12.3
(12.2-12.4) before and 12.3 (12.3-12.3) after case-mix adjustment.
The median (IQR) all-or-none textbook outcome score was 49%
(42%-54%) before and 49% (48%-51%) after case-mix adjustment.
Besides a reduction in hospital variation, the individual hospital
score increased or decreased after case-mix adjustment (Fig. 3).
For the continuous textbook outcome, the standardized rate for
the individual hospital scores ranged between 94 and 102. After
case-mix adjustment, the score increased with a range between
0.1 and 2.1 points in 13 hospitals, the score did not change in 14
hospitals, and the score decreased with a range between 0.1 and
Figure 1. Between-hospital variation in quality indicator scores.
6 VALUE IN HEALTH - 20200.6 points in 64 hospitals. For the all-or-none textbook outcome,
the standardized rate for the individual hospital scores ranged
between 47 and 124. After case-mix adjustment, the score
increased with a range between 0.1 and 2.1 points in 5 hospitals,
the score did not change in 84 hospitals, and the score decreased
with 0.1 point in 2 hospitals.
After ranking hospitals based on their continuous textbook
outcome score, no outliers were identified before and after case-
mix adjustment (Fig. 4). By the all-or-none textbook outcome
approach, 3 (3.3%) hospitals were identified as positive outliers
and 9 (9.9%) hospitals were identified as negative outliers both
before and after case-mix adjustment, meaning that these hospi-
tals had a statistically significantly higher and lower adjusted rate
of textbook outcomes compared to the expected average.Discussion
Sixteen (76%) of 21 Dutch breast cancer process and outcome
quality indicators showed construct validity. Thirteen indicators
were included in the textbook outcome summary measure thatwas achieved in 38 956 (49%) patients. Case mix–adjusted hospital
variation in textbook outcome among 91 hospitals was present,
and 9 (9.8%) negative and 3 (3.3%) positive outlier hospitals could
be identified by the all-or-none method.
The strength of association between indicators showing
construct validity was variable. For indicators with a strong as-
sociation, monitoring and reporting both indicators is superfluous.
For example, irradical BCS and reexcision after BCS were strongly
associated and monitoring both indicators is minimally informa-
tive. Redundancy is under discussion for indicators with a mod-
erate or weak association; they may provide complementary
information.27 Nevertheless, irradical BCS in invasive disease and
irradical BCS in DCIS were weakly to moderately associated, but it
can also be concluded that the lack of a strong correlation means
that achieving radical margins cannot be explained by surgical
performance only and other patient- or tumor-related factors are
of influence. This may be a reason to exclude these indicators from
external hospital performance reports. The composite indicator
breast contour–sparing surgery was designed to replace the
indicator irradical BCS that is believed to falsely stimulate per-
forming mastectomy to keep irradicality rates low. Nevertheless,
Figure 2. Construct validity of hypothesized correlations between indicators.
-- 7testing construct validity showed that breast contour–sparing
surgery is driven by immediate breast reconstruction rates and
merely influenced by irradical BCS rates. A lack of construct val-
idity could result from low numbers of events. For example, the
correlation between being seen by a radiation oncologist prior to
neoadjuvant chemotherapy and MRI prior to neoadjuvant
chemotherapy was not significant in the subcohort of 2015, but
was significant in the total cohort of 2011 to 2016. A lack ofFigure 3. The effect of case-mix adjustment on the standardized rat
unadjusted standardized rate and on the y-axis: case mix–adjusted sta
textbook outcome.
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outcome’construct validity could also imply that the indicators are simply
not valid and do not measure what they intend to measure. We
suggest using these indicators for internal purposes only. In
contrast to our findings, construct validity for quality indicators in
hip replacement and colorectal cancer were limited.27,28
Our textbook outcome summary measure was achieved in 49%
of patients by the all-or-none approach and a median 12.3 of 13
indicators were achieved by the continuous approach. The all-or-e of textbook outcome in 91 hospitals (2011-2016) on the x-axis:
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8 VALUE IN HEALTH - 2020none method sets a higher benchmark and has better discrimi-
native ability,22,29 but results in lower scores.18,22 Textbook
outcome, using the all-or-none approach, has also been studied in
esophageal cancer, gastric cancer, and cholangiocarcinoma, and
was achieved in 23% to 45% of patients.30–32 The average all-or-
none textbook outcome score for colon cancer patients in the
Dutch Surgical Colorectal Audit was found to be 49%, likewise
here, and they identified 8 negative outlier hospitals as compared
to 9 here.21 In contrast to our study, these textbook outcomes
included only 6 to 10 individual quality indicators, which were
applicable to all patients. We found that this is not achievable for a
breast cancer study population because of the more individualized
treatments. Case-mix adjustment reduced between-hospital
variation from an interquartile range of 42% to 54% to 48% to
51% without changing the median all-or-none textbook outcome
score of 49%. More importantly, the ranking position of individual
hospitals changed, emphasizing the importance of case-mix
adjustment. The hospital ranking by continuous score was com-
parable to the hospital ranking by all-or-none score, but outlier
hospitals could only be identified by the all-or-none score. The
larger between-hospital variation and its ability to identify outlier
hospitals makes the all-or-none approach the preferable method
for quality improvement efforts.
A disadvantage of the proposed summary measure is that not
all indicators apply to all breast cancer patients. For example, only
8 of 13 indicators applied to a patient with purely DCIS, and
positive scores were given for the remaining 5 indicators. As a
result, a high score does not necessarily mean better quality of
care. For example, a hospital performing more mastectomies over
BCS does receive points for radical BCS in invasive disease and
radical BCS in DCIS and can still achieve a high textbook outcome
score. Presenting a separate summary score for each subgroup of
breast cancer patients is not possible, because almost each indi-
cator has a different denominator. Also, the influence of each
indicator on quality of care is not equal and weights should be
added. Nevertheless, the simplicity of unweighted measures
encourages implementation.18
An important strength of this study was the large nationwide
study population with almost 80 000 patients treated in more
than 90 different hospitals. The data are relatively complete,accurate, consistent, and reproducible with clear indicator
definitions.25,33,34 Each hospital recorded 99% of its total number
of patients.23 As far as we know, construct validity testing and
constructing a textbook outcome summary measure has not been
done before with quality indicators for breast cancer. The addition
of case-mix adjustment increased the validity of our hospital
comparisons and rankings.7
Next Steps
To enhance implementation of our findings, we suggest
studying within-hospital variation of the textbook outcome to
increase our understanding of the summary measure. A potential
threat of validity is random variation owing to small sample sizes.
Smaller hospitals can have extreme indicator scores simply owing
to chance. Future research should focus on using random effect
models, which can handle random variation, to estimate the
performance of individual hospitals. Further, the validity of the
summary indicator should be tested by relating it to clinically and
patient relevant outcomes. We suggest implementing the sum-
mary measure in several hospitals to further test its validity,
feasibility, and usefulness. For example, the case mix–adjusted
textbook outcome could be presented in a comparative format
followed by the individual indicators. Moreover, we advise
excluding invalid indicators to lower the registration burden. On
the other hand, the increasing focus on quality of life in breast
cancer patients prompts the addition of patient-reported outcome
measures.
Implications
Advantages of a summary measure include reducing the visible
size of the quality indicator set without losing information and
improving the communication of hospital performance to stake-
holders. Stakeholders include patients, and the limited impact of
comparative information on patient hospital choice can be
improved.11–18,35 Caregivers and hospital management can readily
see how they perform compared to the expected or average and
investigate individual indicators in more detail if necessary. Reg-
ulators, such as the NABON, can focus their quality improvement
-- 9efforts on negative outlier hospitals whereby the positive outliers
can function as examples of best practices.1Conclusions
Most (16 of 21) breast cancer process and outcome quality
indicators used in The Netherlands showed construct validity, and
suggestions were made for how to prioritize indicators. We
constructed a textbook outcome summary measure including 13
indicators that was achieved in 49% of patients. Case-mix adjust-
ment reduced the variation among 91 hospitals substantially. In
contrast to the continuous approach of presenting textbook
outcome performance, the all-or-none approach was superior in
its discriminative ability, and 9 (10%) negative and 3 (3%) positive
outlier hospitals could be identified. The summary measure pre-
sented here has the potential to improve the Dutch breast cancer
quality indicator efforts and could be implemented in several
hospitals to further test its validity, feasibility, and usefulness.Supplemental Material
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